>>Peptides>> Peptide Hormones>>ACTH 4-11 (Adrenocorticotropic Hormone (4-11), human)

ACTH 4-11 (Adrenocorticotropic Hormone (4-11), human) (Synonyms: MEHFRWGK-OH)

Catalog No.GC31530

ACTH 4-11(부신피질 자극 호르몬(4-11), 인간), 부신피질 자극 호르몬 단편은 약한 α를 가지고 있습니다.

Products are for research use only. Not for human use. We do not sell to patients.

ACTH 4-11 (Adrenocorticotropic Hormone (4-11), human) Chemical Structure

Cas No.: 67224-41-3

Size 가격 재고 수량
5mg
US$101.00
재고 있음
10mg
US$166.00
재고 있음
25mg
US$358.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

ACTH (4-11), an adrenocorticotropin hormone fragment, possesses a weak α-melanocyte stimulating hormone (α-MSH) potency only at high doses (100 and 1000 nM).

α-melanocyte stimulating hormone (MSH) induces the differentiation of mouse epidermal melanocytes in vivo and in vitro. Adrenocorticotropic hormone (ACTH) possesses the same amino acid sequence as MSH does. α-MSH induces the differentiation of mouse epidermal melanocytes in vivo and in vitro. ACTH (4-11) loses almost all activity for the binding to melanocortin receptor 1 (MC1R)[1].

[1]. Hirobe T, et al. ACTH(4-12) is the minimal message sequence required to induce the differentiation of mouse epidermal melanocytes in serum-free primary culture. J Exp Zool. 2000 May 1;286(6):632-40.

리뷰

Review for ACTH 4-11 (Adrenocorticotropic Hormone (4-11), human)

Average Rating: 5 ★★★★★ (Based on Reviews and 23 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ACTH 4-11 (Adrenocorticotropic Hormone (4-11), human)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.